Stéphane Minvielle

Stéphane Minvielle

Auto-generated profile, based on publicly available information

Stéphane Minvielle

Nantes Université, Inserm, CNRS, Université d’Angers, CRCI2NA, Nantes, France

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
NBNiccolò Bolli
Niccolò Bolli
HAHervé Avet-Loiseau
Hervé Avet-Loiseau
DWDavid Wedge
David Wedge
PLPeter Van Loo
Peter Van Loo
LALudmil B. Alexandrov
Ludmil B. Alexandrov
NMNikhil C. Munshi
Nikhil C. Munshi
Multiple myeloma is an incurable plasma cell malignancy with a complex and incompletely understood molecular pathogenesis. Here we use whole-exome sequencing, copy-number profiling and cytogenetics to analyse 84 myeloma samples. Most cases have a complex subclonal structure and show clusters of subclonal variants, including subclonal driver mutations. Serial sampling reveals diverse patterns of clonal evolution, including linear evolution, differential clonal response and branching evolution. Diverse processes contribute to the mutational repertoire, including kataegis and somatic hypermutation, and their relative contribution changes over time. We find heterogeneity of mutational spectrum across samples, with few recurrent genes. We identify new candidate genes, including truncations of SP140, LTB, ROBO1 and clustered missense mutations in EGR1. The myeloma genome is heterogeneous across the cohort, and exhibits diversity in clonal admixture and in dynamics of evolution, which may impact prognostic stratification, therapeutic approaches and assessment of disease response to treatment.

5 January 2007 in Blood
Verified
Journal Article
Closed access
HAHervé Avet-Loiseau
Hervé Avet-Loiseau
MAMichel Attal
Michel Attal
PMPhilippe Moreau
Philippe Moreau
CCCatherine Charbonnel
Catherine Charbonnel
FGFrédÉrIc Garban
FrédÉrIc Garban
CMClaire Mathiot
Claire Mathiot
Acquired genomic aberrations have been shown to significantly impact survival in several hematologic malignancies. We analyzed the prognostic value of the most frequent chromosomal changes in a large series of patients with newly diagnosed symptomatic myeloma prospectively enrolled in homogeneous therapeutic trials. All the 1064 patients enrolled in the IFM99 trials conducted by the Intergroupe Francophone du Myélome benefited from an interphase fluorescence in situ hybridization analysis performed on purified bone marrow plasma cells. They were systematically screened for the following genomic aberrations: del(13), t(11;14), t(4;14), hyperdiploidy, MYC translocations, and del(17p). Chromosomal changes were observed in 90% of the patients. The del(13), t(11;14), t(4;14), hyperdiploidy, MYC translocations, and del(17p) were present in 48%, 21%, 14%, 39%, 13%, and 11% of the patients, respectively. After a median follow-up of 41 months, univariate statistical analyses revealed that del(13), t(4;14), nonhyperdiploidy, and del(17p) negatively impacted both the event-free survival and the overall survival, whereas t(11;14) and MYC translocations did not influence the prognosis. Multivariate analyses on 513 patients annotated for all the parameters showed that only t(4;14) and del(17p) retained prognostic value for both the event-free and overall survivals. When compared with the currently used International Staging System, this prognostic model compares favorably. In myeloma, the genomic aberrations t(4;14) and del(17p), together with β2-microglobulin level, are important independent predictors of survival. These findings have implications for the design of risk-adapted treatment strategies.

1 October 2009 in Leukemia
Verified
Journal Article
Closed access
PDF file
RFRafael Fonseca
Rafael Fonseca
PBP L Bergsagel
P L Bergsagel
JDJ Drach
J Drach
JSJ Shaughnessy
J Shaughnessy
Norma C. GutiérrezNorma C. Gutiérrez
Norma C. Gutiérrez
HAH Avet-Loiseau
H Avet-Loiseau

15 February 2004 in Cancer Research
Verified
Journal Article
Closed access
PDF file
RFRafael Fonseca
Rafael Fonseca
BBBart Barlogie
Bart Barlogie
RBRegis Bataille
Regis Bataille
CBChristian Bastard
Christian Bastard
PBP. Leif Bergsagel
P. Leif Bergsagel
HAHerve Avet-Loiseau
Herve Avet-Loiseau
Much has been learned regarding the biology and clinical implications of genetic abnormalities in multiple myeloma. Because of recent advances in the field, an International Workshop was held in Paris in February of 2003. This summary describes the consensus recommendations arising from that meeting with special emphasis on novel genetic observations. For instance, it is increasingly clear that translocations involving the immunoglobulin heavy-chain locus are important for the pathogenesis of one-half of patients. As a corollary, it also clear that the remaining patients, lacking IgH translocations, have hyperdiploidy as the hallmark of their disease. Several important genetic markers are associated with a shortened survival such as chromosome 13 monosomy, hypodiploidy, and others. The events leading the transformation of the monoclonal gammopathy of undetermined significance (MGUS) to myeloma are still unclear. One of the few differential genetic lesions between myeloma and MGUS is the presence of ras mutations in the latter. Gene expression platforms are capable of detecting many of the genetic aberrations found in the clonal cells of myeloma. Areas in need of further study were identified. The study of the genetic aberrations will likely form the platform for targeted therapy for the disease.

1 September 2012 in Cancer Cell
Verified
Journal Article
Closed access
DCDharminder Chauhan
Dharminder Chauhan
ZTZe Tian
Ze Tian
BNBenjamin Nicholson
Benjamin Nicholson
KKK.G. Suresh Kumar
K.G. Suresh Kumar
BZBin Zhou
Bin Zhou
KAKenneth Anderson
Kenneth Anderson

20 October 2010 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
HAHervé Avet-Loiseau
Hervé Avet-Loiseau
XLXavier Leleu
Xavier Leleu
MRMurielle Roussel
Murielle Roussel
PMPhilippe Moreau
Philippe Moreau
CGCatherine Guerin-Charbonnel
Catherine Guerin-Charbonnel
JHJean-Luc Harousseau
Jean-Luc Harousseau
Purpose Cytogenetics is an important prognostic parameter in multiple myeloma (MM). Patients presenting with either t(4;14) or del(17p) are known to have a short event-free survival (EFS) and overall survival (OS). Some preliminary data suggest that bortezomib is able to overcome these prognostic parameters. Patients and Methods A series of 507 patients with newly diagnosed MM who received four cycles of bortezomib-dexamethasone induction therapy before high-dose melphalan were analyzed for both t(4;14) and del(17p). Results We found that both t(4;14) and del(17p) remain prognostic parameters, even in the context of bortezomib treatment. However, it is important to note that bortezomib significantly improves the prognosis (in terms of both EFS and OS) of patients with t(4;14), compared with patients treated with vincristine, doxorubicin, and dexamethasone induction therapy. In contrast, no improvement was observed for del(17p) patients. Conclusion Short-term bortezomib induction improves outcome of patients with t(4;14) but not the outcome of patients with del(17p). However, both abnormalities remain prognostic factors predicting both EFS and OS despite bortezomib induction.